Skip to main content
SpringerLink
Log in

Insulin Use

  • Chapter
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome

Part of the book series: Current Clinical Practice ((CCP))

  • 1550 Accesses

Abstract

Several clinical trials covering thousands of patient cohorts have clearly demonstrated the correlation between the long-term macrovascular and microvascular complications of diabetes and poorly controlled blood glucose with the subsequent benefits of tighter glycemic control. This data indicates that insulin use (even in the early stages of diabetes) to insure proper glycemic control can be invaluable in reducing mortality and morbidity. In fact, earlier insulin use reduces glucose toxicity, allows endogenous insulin to function more efficiently, and reduces strain on the deteriorating β-cell (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bastyr EJ, Stuart CA, Brodows RG, et al. (2000) Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 23:1236–1241.

    Article  PubMed  CAS  Google Scholar 

  2. Mayfield J, White RD. (2004) Insulin therapy for type 2 diabetes: rescue, augmentation and replacement of beta-cell function. Am Fam Physician 70:489–500.

    PubMed  Google Scholar 

  3. Burge MR, Schade DS. (1997) Insulins. Endocrinol Metab Clin North Am 26:575–598.

    Article  PubMed  CAS  Google Scholar 

  4. American Diabetes Association. (2002) Standards of medical care for patients with diabetes mellitus. Diabetes Care 25(Suppl 1):S33–S49.

    Google Scholar 

  5. Hermann LS. (2000) Optimizing therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 17:283–294.

    Article  PubMed  CAS  Google Scholar 

  6. Mudaliar S, Edelman SV. (2001) Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 30:935–982.

    Article  PubMed  CAS  Google Scholar 

  7. United Kingdom Prospective Diabetes Study (UKPDS) Group. (1998) A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes (UKPDS 28). Diabetes Care 21:87–92.

    Article  Google Scholar 

  8. Turner RC, Holman R, Stratton I. (1999) Correspondence. The United Kingdom Prospective Diabetes Study (UKPDS). Lancet 352:1934.

    Article  Google Scholar 

  9. van den Berghe G, Wouters P, Weekers F, et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367.

    Article  PubMed  Google Scholar 

  10. Malmberg K. (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarcion in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarcion) Study Group. BMJ 314:1512–1515.

    PubMed  CAS  Google Scholar 

  11. The Diabetes Control and Complications Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986.

    Article  Google Scholar 

  12. Ohkubo Y, Kishikawa H, Araki E, et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–107.

    Article  PubMed  CAS  Google Scholar 

  13. de Veciana M, Major CA, Morgan MA, et al. (1995) Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333:1237–1241.

    Article  PubMed  Google Scholar 

  14. Hirsch IB, McGill JB. (1990) Role of insulin management of surgical patients with diabetes mellitus. Diabetes Care 13:980–991.

    Article  PubMed  CAS  Google Scholar 

  15. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. (2000) A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666–1671.

    Article  PubMed  CAS  Google Scholar 

  16. Palumbo PJ. (2004) The case for insulin treatment early in type 2 diabetes. Clev Clin J Med 71:385–386, 391-392, 394.

    Article  Google Scholar 

  17. Holleman F, van den Brand JJ, Hoven RA, et al. (1996) Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 19:1426–1429.

    Article  PubMed  CAS  Google Scholar 

  18. Lepore M, Pampanelli S, Fanelli C, et al. (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148.

    Article  PubMed  CAS  Google Scholar 

  19. Antsiferov M, Woodworth JR, Mayorov A, et al. (1995) Within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. Diabetologia 38(Suppl 1):A190.

    Google Scholar 

  20. Kelly JL, Hirsch IB, Trence DL. (2002) Rapid decrease in clinically significant hypoglycemia with insulin glargine. Diabetes 51(Suppl 2):A123.

    Google Scholar 

  21. Cefalu WT. (2001) Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann Med 33:579–586.

    PubMed  CAS  Google Scholar 

  22. Owens DR, Zinman B, Bolli GB. (2001) Insulins today and beyond. Lancet 358:739–746.

    Article  PubMed  CAS  Google Scholar 

  23. Home PD, Lindholm A, Hylleberg B, Round P. (1998) Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 21:1904–1909.

    Article  PubMed  CAS  Google Scholar 

  24. Kovisto VA, Tuominen JA, Ebeling P. (199) Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22:459–462.

    Article  Google Scholar 

  25. Rosenfalck AM, Thorsby P, Kjems L, et al. (2000) Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 37:41–46.

    Article  PubMed  CAS  Google Scholar 

  26. Malone JK, Woodworth JR, Arora V, et al. (2000) Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 22:222–230.

    Article  PubMed  CAS  Google Scholar 

  27. Rosskamp RH, Park G. (1999) Long-acting insulin analogs. Diabetes Care 22(Suppl 2):B109–B113.

    PubMed  Google Scholar 

  28. Lepore M, Kurzhals R, Pampanelli S. (1999) Pharacokinetics and dynamics of sup cu injection of the long acting insulin glargine (HOE 1) in TIDM. Diabetes 48(Suppl 1):A97.

    Google Scholar 

  29. Yki-Jarvinen H. (2001) Combination therapies with insulin intype 2 diabetes. Diabetes Care 24:758–767.

    Article  PubMed  CAS  Google Scholar 

  30. Rosenstock J, Riddle MC, Dailey G. (2001) Treatment of target study: feasibility of achieving control with the addition of basal insulin, glargine or NPH in insulin naive patient with type 2 diabetes on oral agents. Diabetes 50(Suppl 2):A520.

    Google Scholar 

  31. Rosentock J, Schwartz SL, Clark CM, Park GD, Donely DW, Edward MB. (2001) Basal insulin therapy in type 2 diabetes: 28-week comparision of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636.

    Article  Google Scholar 

  32. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130:389–396.

    PubMed  CAS  Google Scholar 

  33. Wolffenbuttel BH, Gomis R, Squartrito S, Jones NP, Patwardhan RN. (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17:40–47.

    Article  PubMed  CAS  Google Scholar 

  34. Yki-Jarvinen H, Ryysy L, Kauppila M, et al. (1997) Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:4037–4043.

    Article  PubMed  CAS  Google Scholar 

  35. Buse J. (2000) Combining insulin and oral agents. Am J Med 108(Suppl 6a):23S–32S.

    Article  PubMed  CAS  Google Scholar 

  36. Buse JB. (1999) The use of insulin alone and in combination with oral agents in type 2 diabetes. Prim Care 26:931–950.

    PubMed  CAS  Google Scholar 

  37. Smith AM, Woods TJ, Williams DJ. (2002) Trandermal basir insulin delivery through microspheres. Program and abstracts of the 62nd scientific sessions of the American Diabetes Association. September 14–18, San Francisco. Abstract 191-OR. Diabetes 51 (Suppl 2).

    Google Scholar 

  38. Roberts S. (2003) Amylin analogs. Diabetes self management May/June:49–52.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

(2005). Insulin Use. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press. https://doi.org/10.1385/1-59259-932-X:93

Download citation

  • DOI: https://doi.org/10.1385/1-59259-932-X:93

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-471-5

  • Online ISBN: 978-1-59259-932-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation